HC Wainwright Boosts Genmab A/S (NASDAQ:GMAB) Price Target to $36.00

Key Points

• HC Wainwright has increased its price target for Genmab A/S from $35.00 to $36.00, indicating a potential upside of 56.66% from the current stock price.
• Analysts have a consensus rating of "Moderate Buy" for Genmab A/S, with an average target price of $37.60, while one analyst has rated it a sell.
• The company reported a $0.54 EPS, surpassing analysts' expectations of $0.39, with a net margin of 37.53% for the latest quarter.

Genmab A/S (NASDAQ:GMAB - Free Report) had its price target boosted by HC Wainwright from $35.00 to $36.00 in a research note issued to investors on Friday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Genmab A/S's Q1 2026 earnings at $0.34 EPS, Q2 2026 earnings at $0.62 EPS, Q3 2026 earnings at $0.68 EPS, Q4 2026 earnings at $0.75 EPS and FY2026 earnings at $2.38 EPS.

Other analysts also recently issued reports about the stock. Wall Street Zen upgraded shares of Genmab A/S from a "hold" rating to a "buy" rating in a research report on Monday, July 28th. Truist Financial raised their price target on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Genmab A/S has a consensus rating of "Moderate Buy" and a consensus target price of $37.60.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB traded up $0.3250 during trading on Friday, hitting $24.1450. The company had a trading volume of 554,946 shares, compared to its average volume of 1,433,216. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $27.94. The firm has a market capitalization of $15.49 billion, a P/E ratio of 12.12, a price-to-earnings-growth ratio of 6.80 and a beta of 0.95. The stock has a 50 day simple moving average of $21.84 and a 200 day simple moving average of $20.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The company had revenue of $925.00 million during the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. As a group, analysts predict that Genmab A/S will post 1.45 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

Institutional investors have recently added to or reduced their stakes in the company. Evergreen Capital Management LLC bought a new stake in Genmab A/S in the 2nd quarter worth approximately $200,000. Headlands Technologies LLC grew its holdings in shares of Genmab A/S by 551.7% in the second quarter. Headlands Technologies LLC now owns 10,166 shares of the company's stock valued at $210,000 after purchasing an additional 8,606 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Genmab A/S by 4,407.5% in the second quarter. Tower Research Capital LLC TRC now owns 46,653 shares of the company's stock valued at $964,000 after purchasing an additional 45,618 shares in the last quarter. Captrust Financial Advisors increased its position in Genmab A/S by 2.4% in the second quarter. Captrust Financial Advisors now owns 22,442 shares of the company's stock worth $464,000 after purchasing an additional 526 shares during the last quarter. Finally, Vident Advisory LLC raised its stake in Genmab A/S by 154.4% during the second quarter. Vident Advisory LLC now owns 31,482 shares of the company's stock valued at $650,000 after purchasing an additional 19,105 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.